Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560065 | 1.00 | TRPV4 (0.39) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL16098127 | 0.88 | TRPV4 (0.38) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL16581287 | 0.82 | GPR35 (0.41) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL3230060 | 0.78 | ADRB2 (0.42) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL22119985 | 0.78 | KHK (0.39) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL25190108 | 0.78 | CYP11B1 (0.37) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL30881823 | 0.78 | ESR1 (0.37) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL18130719 | 0.78 | CYP11B1 (0.37) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL14321234 | 0.78 | TSHR (0.35) | TRPV4CYP11B1CYP11B2MAOBMAOA | |
| SCHEMBL30673306 | 0.78 | ESR1 (0.39) | TRPV4CYP11B1CYP11B2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745974-A | Chiral near ultraviolet organic electroluminescent material, preparation method thereof and application thereof in CP-OLED | 华南理工大学 | 2023-03-07 | — | — | CN | claimed |
| US-20260132124-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX, INC. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-12545664-B2 | Composition of matter for use in organic light-emitting diodes | KYULUX, INC. (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12486449-B2 | Organic molecules for use in organic optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-12-02 | — | — | US | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| US-20250042853-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4428125-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-118119601-A | Bicyclic compounds and uses thereof | 贝达药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114971-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SEPRACOR INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | TRPV4 3413/4885CYP11B1 778/4885CYP11B2 841/4885 |
| US-12545664-B2 | Composition of matter for use in organic light-emitting diodes | OPRD1, NR1H2, NR1H3 | TRPV4 2992/4885CYP11B1 285/4885CYP11B2 329/4885 |
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TRPV4 980/4885CYP11B1 2064/4885CYP11B2 1952/4885 |
| US-12486449-B2 | Organic molecules for use in organic optoelectronic devices | OR10J3, OR51E2, OCIAD2 | TRPV4 413/4885CYP11B1 657/4885CYP11B2 283/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | TRPV4 4695/4885CYP11B1 3178/4885CYP11B2 2079/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TRPV4 3413/4885CYP11B1 778/4885CYP11B2 841/4885 |
| US-20260132124-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | OPRD1, NR1H2, NR1H3 | TRPV4 3077/4885CYP11B1 268/4885CYP11B2 322/4885 |
| US-20250042853-A1 | BICYCLIC COMPOUND AND APPLICATION THEREOF | CYP11B2, CYP11B1, CYP17A1 | TRPV4 1257/4885CYP11B1 2/4885CYP11B2 1/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TRPV4 3413/4885CYP11B1 778/4885CYP11B2 841/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | TRPV4 4695/4885CYP11B1 3178/4885CYP11B2 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.